European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapy
Drug developers are racing to make gene therapies that could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a company based just outside of Boston is poised to become ...
Original Source
Read the full article at Endpoints →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.